Form 8-K Revance Therapeutics, For: Aug 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
William Blair Downgrades Revance Therapeutic (RVNC) to Market Perform
August 12, 2024 11:12 AM EDTWilliam Blair analyst Tim Lugo downgraded Revance Therapeutic (NASDAQ: RVNC) from Outperform to Market Perform.
The analyst comments "Before the market open on Monday, August 12, Revance announced Crown Laboratories, a privately held, global leader in the skincare industry, will commence and... More
Stifel Downgrades Revance Therapeutic (RVNC) to Hold Following Go Private Deal
August 12, 2024 10:07 AM EDTStifel analyst Annabel Samimy downgraded Revance Therapeutic (NASDAQ: RVNC) from Buy to Hold with a price target of $6.66 (from $20.00).
The analyst comments "Surprising to us, RVNC announced this morning its intention to merge with Crown Laboratories, a privately-held, global skincare company for... More
